INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
20 Posts Not to Miss from ESMO Congress 2026: Day 2
DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
Inside ESMO 2026 with Amol Akhade
Lacy Hubbard: Rwanda Reaches a Major Milestone in HPV Screening With Mission 2027
Amol Akhade and Mohana Murali Kolluri at COGC 2026: The Cancer Care Gap in Asia-Pacific
Paris Hilton and Kathy Hilton Host Pink Fundraiser for Breast Cancer Research in Beverly Hills
London Global Cancer Week 2026 Speakers
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
